AI summary by TwinMind

Extra: Why Is 23andMe Going Under? (Update) | Freakonomics Radio

Freakonomics Radio Network

1h 2m 4s

Introduction and Context

  • Steven Dubner introduces bonus episode about 23andMe's dramatic decline
  • Company valued at $6 billion in 2021 after going public via SPAC backed by Richard Branson
  • Current valuation: effectively zero according to Wall Street Journal reporter Ralph Winkler
  • Episode replays 2019 interview with CEO Anne Wojcicki with updated analysis

Golden State Killer Case and DNA Privacy Concerns

  • 2018 arrest of Golden State killer using DNA genealogy through GEDmatch
  • Detectives uploaded suspect DNA to open-source genealogy site
  • 24 relatives found in database, cross-referenced with census/cemetery records
  • Raised concerns about privacy and law enforcement use of consumer DNA data
  • Wojcicki emphasized 23andMe's early focus on preventing crime/FBI misuse through consent forms

Anne Wojcicki Background and Company Origins

  • Youngest of three daughters: Stanley Wojcicki (Stanford physics professor), Esther Wojcicki (educator/journalist)
  • Sister Susan was YouTube CEO, sister Janet is anthropologist/epidemiologist
  • Google connection: Susan rented garage to Larry Page/Sergey Brin; Anne married Sergey Brin (divorced 2015)
  • Yale biology degree, varsity ice hockey, Wall Street healthcare analyst for 10 years
  • Became cynical about healthcare system profiting from illness, not wellness
  • Larry Page challenged her: "part of solution or part of problem"

Company Formation and Business Model

  • Co-founded 23andMe in 2006 with Linda Avey and Paul Cusenza
  • Direct-to-consumer personal genomics company
  • $100 ancestry test, additional $100 for health reports
  • 10 million total customers, 5 million bought health reports
  • World's largest genetic database for medical research

FDA Regulatory Challenges

  • November 2013: FDA warning letter demanding halt to health information
  • Company didn't believe they were medical device, FDA disagreed
  • Had to stop interpreting health data, continue raw data/ancestry only
  • Wojcicki: "grateful to FDA" for safety oversight despite initial upset
  • 2017: FDA approved genetic risk reports for 10 conditions including breast/ovarian cancer, Alzheimer's, Parkinson's

Health Risk Reports and Polygenic Scoring

  • 2019: Launched type 2 diabetes risk report using polygenic risk scores
  • Used data from 2.5 million consenting customers
  • Method analyzes thousands/millions of small genetic effects vs single genes
  • Criticized for being "tuned for skinny white people" due to European-heavy database
  • 20% of customers non-European, but largest such database globally

Diversity and Representation Issues

  • Database overwhelmingly European descent, problematic for conditions like diabetes affecting African Americans disproportionately
  • Historical medical exploitation of African Americans creates participation reluctance
  • Global genetic diversity project recruiting from Tanzania, Cameroon, Chad with free testing
  • Goal: develop reports representative of all populations

Behavioral Change and Health Outcomes

  • Limited evidence genetic risk information leads to sustained behavior change
  • Harvard study: 40% reported diet changes at 6 months, but self-reported data unreliable
  • 2016 British Medical Journal: no evidence genetic testing changes behaviors
  • Wojcicki optimistic about human potential for change with right tools
  • Partnerships with AI coaching (Lark) to help behavior modification

Research Partnerships and Data Monetization

  • 2018: GSK $300 million investment for drug discovery rights
  • Additional partnerships: Pfizer, Genentech, Procter & Gamble
  • Over 150 publications, hundreds of studies across diseases
  • Massive disease cohorts: 19,000 Parkinson's, 1 million high Alzheimer's risk, 800,000 heart disease
  • 13-14 compounds in research/development pipeline
  • Customers want results, not $50 checks for data use

Privacy and Security Measures

  • Banking-level security infrastructure from early days
  • Never been substantially hacked (as of 2019 interview)
  • Explicit consent required for individual-level data sharing
  • Pioneered granular sharing options vs restrictive HIPAA model
  • Customer choice emphasized: opt-in/opt-out flexibility

Family Revelations and Genetic Discoveries

  • Personal example: Sergey Brin's Parkinson's mutation discovery
  • Wojcicki family discovered unknown cousin through platform
  • Redefining family connections, especially for Holocaust survivors
  • New literary genre: DNA discovery memoirs revealing family secrets
  • End of anonymous adoption/sperm donation era
  • Powerful psychological impact of genetic vs mirror-based identity

Company Decline Analysis (Ralph Winkler Interview)

  • SPAC projections failed: promised 1 million subscription customers, fell far short
  • One-time product problem: customers only test once, no recurring revenue
  • Subscription model ($70/year) failed to gain traction
  • Drug discovery takes decades, clinical trials uncertain
  • 2023 hack damaged consumer trust (ashkenazi Jewish data targeted)
  • Current enterprise value: zero (stock price equals cash in bank)

Current State and Future Prospects

  • Wojcicki controls 49.99% voting shares, considering taking company private
  • Two cancer drugs in clinical trials
  • Winkler believes company sincere about healthcare mission despite business failure
  • Prediction: similar operations under private ownership within 2-3 years
  • Fundamental challenge: monetizing wellness vs illness remains unsolved

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome